Siglec inhibitors

Details Siglec inhibitors Siglec inhibitors

2002-06-07

2010-10-26

Oh, Taylor Victor (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S023000, C549S419000

Reexamination Certificate

active

07820714

ABSTRACT:
The invention relates to Siglec inhibitors that have an increased affinity for the receptor molecule. The Siglec inhibitors provided by the invention are preferably selective of a given Siglec molecule. The invention further relates to a method for producing Siglec inhibitors and to a method for increasing the binding selectivity for a given Siglec molecule. The invention also relates to pharmaceutical compositions that contain the Siglec inhibitors and to medical indications for the Siglec inhibitors.

REFERENCES:
patent: WO 92/22301 (1992-12-01), None
Crocker et al., “Siglecs: A Family of Sialic-acid Binding Lectins,”Glycobiology, 8(2): v-vi (1998).
Crocker et al., “The Siglec Family of I-Type Lectins,”Carbohydrates in Chemistry and Biology, Ernst et al. (Ed.) (Wiley-VCH, Weinheim) 4: 579-595 (2000).
Crocker et al., “Siglecs in the Immune System,”Immunology, 103: 137-145 (2001).
Kelm, “Ligands for Siglecs,”Mammalian Carbohydrate Recognition Systems, P.R. Crocker (Ed.) (Springer, Berlin ) 153-176 (2001).
Li et al., “Cloning and Characterization of Siglec-10, a Novel Sialic Acid Binding Member of the Ig Superfamily, from Human Dendritic Cells,”J. Biol. Chem., 276(30): 28106-28112 (2001).
May et al., “Crystal Structure of the N-Terminal Domain of Sialoadhesin in Complex with 3′ Sialyllactose at 1.85 Å Resolution,”Molecular Cell, 1: 719-728 (1998).
Strenge et al., “Glycan Specificity of Myelin-associated Glycoprotein and Sialoadhesin Deduced from Interactions with Synthetic Oligosaccharides,”Eur. J. Biochem., 258: 677-685 (1998).
Kelm et al., “Functional Groups of Sialic Acids Involved in Binding to Siglecs (sialoadhesins) Deduced From Interactions with Synthetic Analogues,”Eur. J. Biochem., 255: 663-672 (1990).
Kelm et al., “The Ligand-binding Domain of CD22 is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound,”J. Exp. Med., 195(9): 1207-1213 (2002).
Mirelis et al., “Photoreactive CMP-Sialic Acids as Substrates for α2,6-Sialyltransferase,”Bioorganic&Medicinal Chemistry Letters, 5(23): 2809-2814 (1995).
Murakami et al., “Chemoenzymatic Synthesis of Neuraminic Acid Analogs Structurally Varied at C-5 and C-9 as Potential Inhibitors of the Sialidase from Influenza Virus,”Carbohydrate Research, 280: 101-110 (1996).
Norton et al., “The Sythesis of C-9 Modified Derivatives of the α-Methyl Glycoside of KDN Methyl Ester,”J Carbohydrate Chemistry, 20(2): 227-238 (2001).
Troncoso et al., “Specificity of the Binding Site of the Sialic Acid-binding Lectin from Ovine Placenta, Deduced from Interactions with Synthetic Analogues,”Glycoconjugate Journal, 17: 705-711 (2000).
Ogawa et al., “Synthesis of carbocylic analogues of 3-deoxy-D-manno-2-octulosonic acid andN-acetylneuraminic acid”,Carbohydrate Research269, pp. 53-78 (1995).
Sparks et al., “Neuraminidase-Resistant Hemagglutination Inhibitors: Acrylamide Copolymers Containing a C-Glycoside ofN-Acetylneuraminic Acid”,J. Med. Chem.36, pp. 778-783 (1993).

Affiliated with

Also associated with

Rating

Siglec inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Siglec inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Siglec inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4202207